Gavin P Dowling
Overview
Explore the profile of Gavin P Dowling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ali-Thompson S, Daly G, Dowling G, Kilkenny C, Cox L, McGrath J, et al.
Front Oncol
. 2024 May;
14:1355353.
PMID: 38769947
Aim: The overamplification of human epidermal growth factor (HER2) in breast cancer (BC) has been the subject of numerous research publications since its discovery in 1987. This is the first...
12.
Dowling G, Hehir C, Daly G, Hembrecht S, Keelan S, Giblin K, et al.
Breast
. 2024 May;
76:103749.
PMID: 38759577
Purpose: There are a wide variety of intraoperative techniques available in breast surgery to achieve low rates for positive margins of excision. The objective of this systematic review was to...
13.
Keelan S, Dowling G, Roche T, Hegarty A, Davey M, Dhannoon A, et al.
Br J Surg
. 2024 Mar;
111(3).
PMID: 38498075
Background: Electrosurgical devices are commonly used during mastectomy for simultaneous dissection and haemostasis, and can provide potential benefits regarding vessel and lymphatic ligation. The aim of this prospective RCT was...
14.
Daly G, Alrawashdeh M, McGrath J, Dowling G, Cox L, Naidoo S, et al.
Curr Oncol Rep
. 2024 Jan;
26(2):103-113.
PMID: 38236558
Purpose Of Review: In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims...
15.
Dowling G, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, et al.
BMC Cancer
. 2024 Jan;
24(1):91.
PMID: 38233810
Background: The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted...
16.
Dowling G, Daly G, Keelan S, Boland F, Toomey S, Hill A, et al.
Clin Breast Cancer
. 2023 Sep;
23(8):847-855.e2.
PMID: 37775347
Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug-conjugate (ADC), primarily used in the treatment of HER2-positive breast cancer. This study aimed to conduct a systematic review to evaluate the efficacy and...
17.
Dowling G, Keelan S, Toomey S, Daly G, Hennessy B, Hill A
Front Oncol
. 2023 Feb;
13:1066007.
PMID: 36793602
Purpose: The development of human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of HER2-positive breast cancer. The aim of this article is to review the continually...
18.
Dowling G, Piccin A, Gavin K, Betts D, Malone A, Cotter M, et al.
Ir J Med Sci
. 2020 Feb;
189(3):979-984.
PMID: 32006388
Background: Acute megakaryoblastic leukaemia (AMKL) is a subtype of myeloid leukaemia and is the most common leukaemia type in children with Down syndrome (DS) under 4 years of age. AMKL...